Table I.

Circulating cytokines, growth factors, and hormones in acute IL-1β–treated mice

Treatment IL-6 IL-1β IGF-1 Corticosterone 
 pg/ml pg/ml ng/ml ng/ml 
2-h Veh 13 ± 3 22 ± 6 225 ± 11 104 ± 16 
2-h 10-ng IL-1β 298 ± 35*** 25 ± 6 216 ± 18 397 ± 30*** 
4-h Veh 21 ± 6 16 ± 3 200 ± 8 103 ± 14 
4-h 10-ng IL-1β 69 ± 14 28 ± 6 168 ± 9 258 ± 35*** 
8-h Veh 13 ± 6 46 ± 15 173 ± 4 115 ± 34 
8-h 10-ng IL-1β 8 ± 2 32 ± 5 205 ± 6 72 ± 10 
Treatment IL-6 IL-1β IGF-1 Corticosterone 
 pg/ml pg/ml ng/ml ng/ml 
2-h Veh 13 ± 3 22 ± 6 225 ± 11 104 ± 16 
2-h 10-ng IL-1β 298 ± 35*** 25 ± 6 216 ± 18 397 ± 30*** 
4-h Veh 21 ± 6 16 ± 3 200 ± 8 103 ± 14 
4-h 10-ng IL-1β 69 ± 14 28 ± 6 168 ± 9 258 ± 35*** 
8-h Veh 13 ± 6 46 ± 15 173 ± 4 115 ± 34 
8-h 10-ng IL-1β 8 ± 2 32 ± 5 205 ± 6 72 ± 10 

WT mice received i.c.v. injections of IL-1β. Animals were sacrificed at 2, 4, and 8 h after the injection (n = 6-9/group). Plasma IL-6, IL-1β, and IGF-1 levels were measured by ELISA and corticosterone was measured by RIA. ***, P < 0.001 versus corresponding Veh-injected control as calculated by two-way ANOVA with Bonferroni’s post test.

or Create an Account

Close Modal
Close Modal